<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00866073</url>
  </required_header>
  <id_info>
    <org_study_id>00331</org_study_id>
    <nct_id>NCT00866073</nct_id>
  </id_info>
  <brief_title>Study of Low-Dose Intravenous Decitabine in Patients Aged &gt; 60 Years With Acute Myeloid Leukemia</brief_title>
  <official_title>Phase II Study of Low-Dose Intravenous Decitabine in Patients Aged &gt; 60 Years With Acute Myeloid Leukemia Who Are Not Eligible for Standard Induction Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Freiburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label phase II trial to investigate the efficacy and toxicity of&#xD;
      low-dose decitabine (5-aza-2'-deoxycytidine) in elderly patients with acute myeloid leukemia&#xD;
      (AML) not eligible for aggressive induction chemotherapy. AML patients above the age of 60&#xD;
      years (no upper age limit) who have not previously received and are not eligible for,&#xD;
      standard induction treatment of their disease will be eligible for this trial. Decitabine&#xD;
      will be administered as a 3 hour infusion at 15 mg/m2 three times daily on three consecutive&#xD;
      days (total dose 135 mg/m2). In all patients with &gt; 20000 WBC/µl, this treatment will be&#xD;
      repeated 1 week later. In patients with white blood cells exceeding 50 000/μl, decitabine&#xD;
      treatment will be preceded by cytoreductive doses of hydroxyurea.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: If after 4 courses of Decitabine none out of 12 patients achieves a response&#xD;
      (complete or partial remission, antileukemic effect), the protocol will be stopped. If at&#xD;
      least one response is seen among the first 12 patients, 17 additional patients will be&#xD;
      treated in an open, uncontrolled manner. If in 3 or more of these 29 patients a response is&#xD;
      achieved, this treatment will be considered effective and will be studied further, otherwise&#xD;
      it will be considered ineffective. At a preliminary analysis after recruitment of 29&#xD;
      patients, encouraging results (response rate, tolerability) are prompting continuation of&#xD;
      recruitment, with a planned inclusion of at least 60 patients, until initiation of the&#xD;
      planned large, controlled phase II follow-up trial. Unexpected toxicities will be carefully&#xD;
      evaluated. 29 patients were needed for the first two steps of this phase II study, at least&#xD;
      60 patients are planned for the extension of the recruitment. Expected study duration for the&#xD;
      first two steps was 15-20 months, with 35-40 months total when including the third step.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate (complete and partial remissions, antileukemic effect)</measure>
    <time_frame>after four treatment courses of Decitabine, after 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>after 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival time</measure>
    <time_frame>after 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity of Decitabine (alone and in combination with all-trans retinoic acid)</measure>
    <time_frame>after 3-6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">238</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Decitabine 15 mg/m2 i.v. - single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine 15 mg/m2 i.v.</intervention_name>
    <description>Decitabine at 15 mg/m2 i.v. x 3 hours, three times daily on three consecutive days</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Dacogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients older than 60 years with acute myeloid leukemia (&gt; 30 % bone marrow blasts)&#xD;
             not qualifying for, or not consenting to, standard induction chemotherapy or immediate&#xD;
             allografting&#xD;
&#xD;
          -  life expectancy &gt; 3 months with successful treatment&#xD;
&#xD;
          -  performance status ECOG 0, 1, 2&#xD;
&#xD;
          -  age-adjusted normal cardiac, kidney, liver function (creatinine &lt; 1.5 mg/dl unless&#xD;
             leukemia-related, total bilirubin &lt; 2.0 of upper normal limits)&#xD;
&#xD;
          -  patients with &gt;50 000 leukocytes/µl in whom initial cytoreduction according to&#xD;
             protocol is effective&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  AML of FAB subtype M3&#xD;
&#xD;
          -  previous induction-type chemotherapy for MDS or AML&#xD;
&#xD;
          -  previous treatment with Decitabine, 5-azacytidine or ATRA&#xD;
&#xD;
          -  &quot;low-dose&quot; chemotherapy (e.g.hydroxyurea, cytosine arabinoside, melphalan) within 8&#xD;
             weeks prior to Decitabine treatment, except for cytoreduction of leukocytosis &gt; 50&#xD;
             000/µl according to protocol - patients with &gt; 50 000 leukocytes/µl in whom initial&#xD;
             cytoreduction according to protocol is ineffective&#xD;
&#xD;
          -  treatment with cytokines within previous 4 weeks&#xD;
&#xD;
          -  concomitant use of any other investigational drug&#xD;
&#xD;
          -  other malignancy that is not in remission (previous chemotherapy for other&#xD;
             malignancies is not an exclusion criteria)&#xD;
&#xD;
          -  cardiac insufficiency NYHA IV&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  other uncontrolled active infection&#xD;
&#xD;
          -  psychiatric disorder that interferes with treatment&#xD;
&#xD;
          -  known hypersensitivity to retinoids&#xD;
&#xD;
          -  contact lenses&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Lübbert, Prof Dr med</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Freiburg - Dept. of Oncology/Hematoloy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Technischen Universität Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katholisches Krankenhaus Hagen</name>
      <address>
        <city>Hagen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Lüdenscheid</name>
      <address>
        <city>Luedenscheid</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Villingen-Schwenningen</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leyenburg Hospital</name>
      <address>
        <city>The Hague</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>March 19, 2009</study_first_submitted>
  <study_first_submitted_qc>March 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2009</study_first_posted>
  <last_update_submitted>March 19, 2009</last_update_submitted>
  <last_update_submitted_qc>March 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. med. M. Lübbert</name_title>
    <organization>Dept. of Oncology/Hematology - University Medical Center Freiburg</organization>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>Decitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

